课题基金 / 基金详情

An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer

An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer
乳腺癌中 CXCL12-CXCR4 轴通过核 LASP-1 的表观遗传联系
批准号:
9204937
负责人:
Dayanidhi Raman
金额:
$19.77万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-12-01 至 2017-11-30
关键词:
AMD3100AgarAmino AcidsAnchorage-Independent GrowthAntibodiesAreaBindingBiochemicalBiologicalBiological AssayBone ResorptionBreast Cancer CellBreast Cancer PatientBreast Cancer cell lineBreast cancer metastasisCXC ChemokinesCXCL12 geneCXCR3 geneCXCR4 geneCancer EtiologyCell NucleusCell membraneCellsCessation of lifeChemotaxisComplexComputer softwareConfocal MicroscopyCytoplasmDentinDominant-Negative MutationE-CadherinEmbryonic DevelopmentEpigenetic ProcessEpithelialEstrogen ReceptorsEventFructose-1,6-BisphosphataseGoalsGrowthHistone H3HistonesIL8RA geneIL8RB geneIn SituIn VitroIndividualKnock-outLabelLigationLightLinkLysineLytic Metastatic LesionMDA MB 231MapsMediatingMesenchymalMetastatic breast cancerMethylationMolecularMutagenesisNeoplasm MetastasisNuclearNucleosomesOsteolyticParnatePeptidesPhenotypePlayPrimary NeoplasmProteinsProteomicsRecombinantsRecruitment ActivityResearchResistanceRoleSUM-159 Breast Cancer Cell LineShapesSiteSite-Directed MutagenesisSnailsSurvival RateTestingTransforming Growth Factor betaTransforming Growth FactorsWomanbonecell motilitychemokinechemokine receptorchemotherapeutic agentchromatin immunoprecipitationdemethylationepigenomeinhibitor/antagonistknock-downmalignant breast neoplasmmatrigelmigrationmortalitymutantnew therapeutic targetnovelparathyroid hormone-related proteinprogramspromoterpublic health relevanceslugsmall molecule inhibitorstemnesstranscription factortriple-negative invasive breast carcinomatumortumor microenvironmenttumor progression

项目摘要

项目成果

Dayanidhi Raman的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): The goal of the proposed research is to investigate the role of CXCL12-driven nuclear LASP1 in modulation of epigenetic events in breast cancer. LASP-1 mediates cell migration, proliferation and survival in several breast cancer cell lines. Silencing of LASP-1 inhibits proliferation and migration by 45%. Previously, LASP-1 was demonstrated to directly interact with CXC chemokine receptors, CXCR1, CXCR2, CXCR3 and CXCR4 that play a key role in the tumor microenvironment facilitating breast cancer progression and metastasis. In particular, LASP-1 augmented CXCR2-mediated cell migration. Epigenetic alterations in breast cancer cells convert them into aggressive and metastatic phenotype. In this study, through proteomics, UHRF1 was discovered as a novel LASP-1 associating protein. Subsequently, DNMT1, G9a and Snail1 were also observed to associate with LASP-1. In particular, Snail1 was found to directly bind to LASP-1. The biological implication of this direct interaction is unclear. First, I propose to map the interaction sites between LASP-1 and Snail1 by mutational and biochemical approaches. I further propose to study the LASP1-Snail1 complex for its ability to modulate the E-cadherin promoter. Additionally, as Snail1 directly binds to lysine demethyalse1 (LSD1), LSD1 will be analyzed whether it associates with LASP1-Snail1 complex by biochemical studies. Functionally, I propose to perform a chromatin immunoprecipitation (ChIP) analysis for LASP-1, LSD1, and K4/9 methylation of histone H3 to see if LASP-1/LSD1 co-localize to regions with demethylated histones upon stimulation with CXCL12. Alternatively, recombinant LASP-1 will be mixed with purified LSD-1 and see if LASP-1 enhances in vitro demethylation activity on labeled histone H3 or nucleosome substrates. Additionally, non-silenced and LASP1-knock down basal- like breast cancer cells will be tested for their ability to facilitate bone resorption in a dentine disk assay. LASP1-Snail1 axis would become a novel drug target for small molecule inhibitors with the aim of prolonging the survival rate especially in triple-negative breast cancer patients. Novel inhibitors might be even more useful in cases of breast cancer that are resistant to current chemotherapeutic agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
国内基金
海外基金
Cd(II)在NH2-Agar/PSS双网络水凝胶上的吸附行为及资源化工艺研究
  • 批准号:
    51708204
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2017
  • 负责人:
    周贵寅
  • 依托单位: